NR4A3: A Potential Drug Target and Biomarker for Neuron-Derived Orphan Receptor 1

Target Name: NR4A3

NCBI ID: G8013

NR4A3

NR4A3: A Potential Drug Target and Biomarker for Neuron-Derived Orphan Receptor 1

Neuron-derived orphan receptor 1 (NR4A3) is a protein that is expressed in various neural tissues, including the brain, and has been implicated in various neurological and psychiatric disorders. Despite its potential as a drug target, little is known about NR4A3, making it an attractive target for researchers to investigate.

NR4A3 is a G protein-coupled receptor (GPCR), which means it interacts with protein molecules called G proteins. GPCR is a family of transmembrane proteins that play a critical role in cellular signaling, including but not limited to intracellular signaling, neurotransmission, and pain signaling. TheNR4A3 gene was identified in 2002 and has been extensively studied since then.

NR4A3 is expressed in various neural tissues, including the brain, and has been shown to be involved in various neurological and psychiatric disorders. For example, NR4A3 has been shown to be involved in the development of Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells.

In addition to its involvement in Alzheimer's disease, NR4A3 has also been shown to be involved in other neurological disorders, including Parkinson's disease, schizophrenia, and depression. NR4A3 has also been shown to be involved in pain signaling, which can contribute to the development and maintenance of chronic pain.

GPCRs are known for their ability to modulate cellular signaling pathways, making them an attractive drug target for researchers. By interacting with GPCRs, drugs can modulate the activity of these proteins and ultimately affect cellular signaling. NR4A3 is no exception.

NR4A3 has been shown to interact with various drugs, including psychotherapeutic drugs, which can modulate its activity. These interactions suggest that NR4A3 may be a drug target that can be modulated by various therapeutic approaches.

In addition to its potential as a drug target, NR4A3 may also be a biomarker for various neurological and psychiatric disorders. For example, NR4A3 has been shown to be involved in the development of Alzheimer's disease, and its levels have been shown to decline in individuals with Alzheimer's disease compared to age-matched controls.

NR4A3 has also been shown to be involved in the development of other neurological disorders, including Parkinson's disease and schizophrenia. It is possible that NR4A3 may be a biomarker for these disorders as well.

In conclusion, NR4A3 is a protein that has been shown to be involved in various neurological and psychiatric disorders. Its potential as a drug target and biomarker make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the role of NR4A3 in cellular signaling and its potential as a drug and biomarker.

Protein Name: Nuclear Receptor Subfamily 4 Group A Member 3

Functions: Transcriptional activator that binds to regulatory elements in promoter regions in a cell- and response element (target)-specific manner. Induces gene expression by binding as monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and as homodimers to the Nur response element (NurRE) site in the promoter of their regulated target genes (By similarity). Plays a role in the regulation of proliferation, survival and differentiation of many different cell types and also in metabolism and inflammation. Mediates proliferation of vascular smooth muscle, myeloid progenitor cell and type B pancreatic cells; promotes mitogen-induced vascular smooth muscle cell proliferation through transactivation of SKP2 promoter by binding a NBRE site (By similarity). Upon PDGF stimulation, stimulates vascular smooth muscle cell proliferation by regulating CCND1 and CCND2 expression. In islets, induces type B pancreatic cell proliferation through up-regulation of genes that activate cell cycle, as well as genes that cause degradation of the CDKN1A (By similarity). Negatively regulates myeloid progenitor cell proliferation by repressing RUNX1 in a NBRE site-independent manner. During inner ear, plays a role as a key mediator of the proliferative growth phase of semicircular canal development (By similarity). Mediates also survival of neuron and smooth muscle cells; mediates CREB-induced neuronal survival, and during hippocampus development, plays a critical role in pyramidal cell survival and axonal guidance. Is required for S phase entry of the cell cycle and survival of smooth muscle cells by inducing CCND1, resulting in RB1 phosphorylation. Binds to NBRE motif in CCND1 promoter, resulting in the activation of the promoter and CCND1 transcription (By similarity). Also plays a role in inflammation; upon TNF stimulation, mediates monocyte adhesion by inducing the expression of VCAM1 and ICAM1 by binding to the NBRE consensus site (By similarity) (PubMed:20558821). In mast cells activated by Fc-epsilon receptor cross-linking, promotes the synthesis and release of cytokines but impairs events leading to degranulation (By similarity). Also plays a role in metabolism; by modulating feeding behavior; and by playing a role in energy balance by inhibiting the glucocorticoid-induced orexigenic neuropeptides AGRP expression, at least in part by forming a complex with activated NR3C1 on the AGRP- glucocorticoid response element (GRE), and thus weakening the DNA binding activity of NR3C1. Upon catecholamines stimulation, regulates gene expression that controls oxidative metabolism in skeletal muscle (By similarity). Plays a role in glucose transport by regulating translocation of the SLC2A4 glucose transporter to the cell surface (PubMed:24022864). Finally, during gastrulation plays a crucial role in the formation of anterior mesoderm by controlling cell migration. Inhibits adipogenesis (By similarity). Also participates in cardiac hypertrophy by activating PARP1 (By similarity)

The "NR4A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NR4A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets